<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="176">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05509387</url>
  </required_header>
  <id_info>
    <org_study_id>#22-19</org_study_id>
    <nct_id>NCT05509387</nct_id>
  </id_info>
  <brief_title>Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease</brief_title>
  <official_title>Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baycrest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baycrest</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing&#xD;
      effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with&#xD;
      transcranial direct current stimulation (tDCS) has the potential to be a clinically effective&#xD;
      therapy for both AD and FTD. The challenge now is to specify the parameters and conditions&#xD;
      under which tDCS is most effective to transition from the laboratory to clinical medicine.&#xD;
      tDCS studies typically report significant group effects despite the variability demonstrated&#xD;
      among participants, with some showing clear, meaningful improvement, while others only show&#xD;
      statistical improvement or none at all. These variable results may be related to the&#xD;
      conventional stimulation intensity level of 2mA. The investigators predict that administering&#xD;
      tDCS at 4.0 mA, a more significant number of participants would show a meaningful response,&#xD;
      and those who improve at 2mA may improve even more from 4.0mA due to having a larger electric&#xD;
      field produced. The investigators aim to test this hypothesis in people with Alzheimer's&#xD;
      Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Naming Training</measure>
    <time_frame>3 months</time_frame>
    <description>The primary outcome measure will be change on the naming lists administered, both a trained version and an untrained version. This change will be measured in terms of the number of images correctly named post-training compared to baseline</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>4mA Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2mA Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHAM</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial direct current stimulation and naming training</intervention_name>
    <description>Participants will receive mild stimulation or no stimulation along with naming training</description>
    <arm_group_label>2mA Stimulation</arm_group_label>
    <arm_group_label>4mA Stimulation</arm_group_label>
    <arm_group_label>SHAM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild to Moderate AD&#xD;
&#xD;
          -  Score between 18 and 25 on the MoCA&#xD;
&#xD;
          -  Score on the Cambridge Naming Task during the pre-assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No history of stroke or TBI&#xD;
&#xD;
          -  No shunts or metal in the body&#xD;
&#xD;
          -  No history of significant heart disease, alcoholism and drug use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos Roncero, PhD</last_name>
    <email>troncero@research.baycrest.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baycrest Health Sciences</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Carlos Roncero, PhD</last_name>
      <phone>416-785-2500</phone>
      <phone_ext>2522</phone_ext>
      <email>troncero@research.baycrest.org</email>
    </contact>
    <contact_backup>
      <last_name>Yashna Kochar, H. BSc</last_name>
      <phone>416-785-2500</phone>
      <phone_ext>2522</phone_ext>
      <email>ykochar@research.baycrest.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>August 18, 2022</study_first_submitted>
  <study_first_submitted_qc>August 18, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2022</study_first_posted>
  <last_update_submitted>August 19, 2022</last_update_submitted>
  <last_update_submitted_qc>August 19, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baycrest</investigator_affiliation>
    <investigator_full_name>Tyler Roncero</investigator_full_name>
    <investigator_title>Scientific Associate</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 9, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT05509387/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 9, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT05509387/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

